9th Nov 2007 07:00
Oxford Biomedica PLC09 November 2007 For Immediate Release 9 NOVEMBER 2007 OXFORD BIOMEDICA ANNOUNCES APPOINTMENT OF JPMORGAN CAZENOVE AS SOLE CORPORATE BROKER AND JOINT FINANCIAL ADVISER Oxford, UK - 9 November 2007: Oxford BioMedica (LSE: OXB), a leading genetherapy company, today announces that it has appointed JPMorgan Cazenove Limitedas its sole corporate broker and joint financial adviser with immediate effect. -Ends- For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 783 000Professor Alan Kingsman, Chief Executive JPMorgan Cazenove Limited Tel: +44 (0)20 7588 2828James Mitford/Gina Gibson City/Financial Enquiries: Tel: +44 (0)20 7466 5000Lisa Baderoon/ Mark Court/ Mary-Jane Johnson BuchananCommunications Scientific/Trade Press Enquiries: Tel: +44 (0)20 7268 3002Gemma Price/ Holly Griffiths/ Katja StoutNorthbank Communications Notes to editors 1. Oxford BioMedicaOxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment and commercialisation of novel therapeutic vaccines and gene-basedtherapies with a focus on oncology and neurotherapy. The Company was establishedin 1995 as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. In oncology, the lead product candidateis TroVax(R), an immunotherapy for multiple solid cancers, which is licensed tosanofi-aventis for global development and commercialisation. A Phase III trialof TroVax in renal cancer is ongoing and two Phase III trials in colorectalcancer are planned. Oxford BioMedica has two other anti-cancer productcandidates in Phase II development for melanoma and pancreatic cancerrespectively. In neurotherapy, the Company has submitted a Clinical TrialApplication to initiate a Phase I/II trial of its gene-based treatment forParkinson's disease, ProSavin(R). The neurotherapy pipeline also includespreclinical gene-based therapeutics for vision loss, motor neuron disease andnerve repair. The Company is underpinned by over 80 patent families, which represent one ofthe broadest patent estates in the field. The Company has a staff ofapproximately 80 split between its main facilities in Oxford and its whollyowned subsidiary, BioMedica Inc, in San Diego, California. Corporate partnersinclude sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibodytherapy. The Company also has collaborations with Sigma-Aldrich, MolMed andVirxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKlineand Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica